Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate
Source: View publication →
In pregnant women with a prior history of spontaneous preterm delivery, weekly injections of 17 alpha-hydroxyprogesterone caproate (17P) significantly reduced the rate of recurrent preterm delivery.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark study established 17-OHPC (later marketed as Makena) as the standard of care for preventing recurrent spontaneous preterm birth for nearly two decades. However, following the negative PROLONG confirmatory trial, the FDA officially withdrew Makena's approval in April 2023, reversing this longstanding practice.
Historical Context
Prior to 2003, small trials evaluating progestational agents for preterm birth prevention yielded conflicting results. The Meis trial, conducted by the NICHD Maternal-Fetal Medicine Units (MFMU) Network, demonstrated such a profound benefit that the FDA granted 17-OHPC accelerated approval in 2011. It heavily influenced ACOG and SMFM guidelines until its efficacy was formally disproven by the FDA-mandated PROLONG study nearly two decades later.
Guided Discussion
High-yield insights from every perspective
How does progesterone theoretically maintain pregnancy and prevent preterm labor, and why was 17 alpha-hydroxyprogesterone caproate (17-OHPC) administered via weekly intramuscular injections rather than orally in the Meis trial?
Key Response
Progesterone maintains uterine quiescence by downregulating gap junctions, inhibiting cervical ripening, and decreasing oxytocin receptor expression. 17-OHPC is a synthetic progestin formulated in castor oil as a depot injection; this route bypasses the extensive first-pass hepatic metabolism that rapidly degrades natural oral progesterone, allowing for sustained, therapeutic systemic levels with weekly dosing.
Based on the inclusion criteria of the Meis trial, which specific patient populations were targeted, and why is it critical to accurately differentiate between a prior 'spontaneous' preterm birth and a 'medically indicated' preterm birth during an obstetric intake?
Key Response
The Meis trial specifically included women with a history of prior spontaneous preterm birth (e.g., preterm labor or premature rupture of membranes). It is critical for residents to differentiate this from medically indicated preterm births (e.g., early delivery for severe preeclampsia or fetal growth restriction), because progesterone supplementation targets the mechanism of spontaneous uterine activity and cervical change, and has no efficacy or indication in preventing medically indicated preterm deliveries.
The Meis trial demonstrated a profound reduction in recurrent preterm birth with 17-OHPC, yet the subsequent international PROLONG trial failed to confirm this benefit. What were the key baseline demographic and risk profile differences between these two study populations that might explain this significant discrepancy in efficacy?
Key Response
The Meis trial cohort had a uniquely high baseline risk, with a placebo preterm birth rate of 54.9%, and a majority African American population with significant historical risk factors. In contrast, the PROLONG trial had a much lower placebo preterm birth rate (around 11.5%) and a predominantly white, European cohort. Fellows must understand that the efficacy of 17-OHPC may be highly dependent on the baseline risk of the population, and such discrepancies highlight the challenges of generalizing trial results across different geographic and demographic cohorts.
Given the FDA's recent withdrawal of 17-OHPC (Makena) based on the negative results of the PROLONG trial, how should you counsel a patient today who had a prior spontaneous preterm birth and strongly requests 17-OHPC because she believes it 'saved' her previous pregnancy?
Key Response
Attendings must navigate the challenging de-adoption of a long-standing standard of care. Counseling involves empathetically validating her experience while explaining that larger, more recent data showed 17-OHPC does not improve neonatal outcomes. The discussion should pivot to current evidence-based management, such as serial transvaginal cervical length screening, and the potential use of vaginal progesterone or cervical cerclage if a short cervix develops.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The Meis trial was stopped early by the Data and Safety Monitoring Board (DSMB) after an interim analysis showed significant efficacy. How does early trial cessation for benefit introduce 'truncation bias' (or 'random high' bias), and how might this statistical phenomenon have impacted the estimated effect size of 17-OHPC?
Key Response
Stopping a trial early for efficacy often captures a random peak in the treatment effect, leading to an overestimation of the true benefit (truncation bias). PhD researchers must recognize that this early cessation likely inflated the absolute risk reduction observed in the Meis trial, which provides a methodological explanation for why subsequent, fully completed trials like PROLONG failed to replicate the massive effect size.
As an editor critically appraising the original Meis manuscript, what concerns would you raise regarding the unusually high rate of preterm birth in the placebo group (54.9%) compared to historical controls, and how does this threaten the external validity of the study?
Key Response
An editor would flag that the 54.9% recurrent preterm birth rate in the placebo arm was drastically higher than the 30-35% historically expected for this demographic. This artificially inflated baseline risk exaggerates the apparent absolute risk reduction and Number Needed to Treat (NNT), threatening external validity by making the intervention look substantially more effective than it would be in a standard clinical population with a normal baseline risk.
In light of the FDA's withdrawal of 17-OHPC and the conflicting data between the Meis and PROLONG trials, how must ACOG and SMFM update their guidelines regarding the prevention of recurrent spontaneous preterm birth, and what level of evidence supports the alternative interventions that should now take precedence?
Key Response
Guidelines must officially pivot away from universally recommending 17-OHPC for a history of spontaneous preterm birth (previously a strong recommendation). The committee must now emphasize Level A evidence supporting serial cervical length surveillance, accompanied by the use of vaginal progesterone or ultrasound-indicated cerclage for patients who develop a short cervix (<25 mm), ensuring a clear, evidence-based pathway remains for high-risk patients.
Clinical Landscape
Noteworthy Related Trials
FMF Short Cervix Trial
Tested
Vaginal progesterone (200 mg daily)
Population
Asymptomatic pregnant women with a short cervix (<= 15 mm) at 20-25 weeks
Comparator
Placebo
Endpoint
Spontaneous delivery before 34 weeks of gestation
OPPTIMUM Trial
Tested
Vaginal progesterone (200 mg daily)
Population
Women at high risk for preterm birth (prior PTB, short cervix, or positive fetal fibronectin)
Comparator
Placebo
Endpoint
Fetal death or birth <34 weeks, and composite neonatal outcome
PROLONG Trial
Tested
17-alpha hydroxyprogesterone caproate (17-OHPC)
Population
Pregnant women with singleton gestation and prior spontaneous preterm birth
Comparator
Placebo
Endpoint
Preterm birth <35 weeks and composite neonatal morbidity/mortality index
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis